WO2023067031A3 - Dosage - Google Patents

Dosage Download PDF

Info

Publication number
WO2023067031A3
WO2023067031A3 PCT/EP2022/079144 EP2022079144W WO2023067031A3 WO 2023067031 A3 WO2023067031 A3 WO 2023067031A3 EP 2022079144 W EP2022079144 W EP 2022079144W WO 2023067031 A3 WO2023067031 A3 WO 2023067031A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
colour
protein
vitro potency
potency assay
Prior art date
Application number
PCT/EP2022/079144
Other languages
English (en)
Other versions
WO2023067031A2 (fr
Inventor
Marta BACCONI
Monia BARDELLI
Brunella Brunelli
Vincent DEWAR
Elisabetta Frigimelica
Carmine MALZONE
Werner Pansegrau
Daniele Veggi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of WO2023067031A2 publication Critical patent/WO2023067031A2/fr
Publication of WO2023067031A3 publication Critical patent/WO2023067031A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un immunoessai multiplex pour analyser un vaccin antiméningococcique et évaluer la puissance relative in vitro de celui-ci (IVRP). L'invention concerne également des anticorps monoclonaux qui se lient aux protéines méningococciques à l'intérieur du vaccin, et en particulier des anticorps monoclonaux qui sont bactéricides pour un méningocoque et/ou qui reconnaissent des épitopes conformationnels dans les protéines méningococciques.
PCT/EP2022/079144 2021-10-21 2022-10-19 Dosage WO2023067031A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115077.6A GB202115077D0 (en) 2021-10-21 2021-10-21 Assay
GB2115077.6 2021-10-21

Publications (2)

Publication Number Publication Date
WO2023067031A2 WO2023067031A2 (fr) 2023-04-27
WO2023067031A3 true WO2023067031A3 (fr) 2023-06-01

Family

ID=78805967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/079144 WO2023067031A2 (fr) 2021-10-21 2022-10-19 Dosage

Country Status (2)

Country Link
GB (1) GB202115077D0 (fr)
WO (1) WO2023067031A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143168A2 (fr) * 2008-05-19 2009-11-26 Novartis Ag Essais de vaccin
WO2012031271A1 (fr) * 2010-09-04 2012-03-08 Novartis Ag Dosages d'anticorps bactéricides pour évaluer l'immunogénicité et la puissance de vaccins contre le méningocoque constitués de saccharides capsulaires
WO2013132040A2 (fr) * 2012-03-08 2013-09-12 Novartis Ag Dosage de puissance in vitro pour des vaccins méningococciques à base de protéine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US5698438A (en) 1994-10-18 1997-12-16 Oregon Health Sciences University Bacterial hemoglobin receptor gene
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
NZ541361A (en) 1998-05-01 2008-04-30 Inst Genomic Research Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
AU2001280883A1 (en) 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP3607967A1 (fr) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143168A2 (fr) * 2008-05-19 2009-11-26 Novartis Ag Essais de vaccin
WO2012031271A1 (fr) * 2010-09-04 2012-03-08 Novartis Ag Dosages d'anticorps bactéricides pour évaluer l'immunogénicité et la puissance de vaccins contre le méningocoque constitués de saccharides capsulaires
WO2013132040A2 (fr) * 2012-03-08 2013-09-12 Novartis Ag Dosage de puissance in vitro pour des vaccins méningococciques à base de protéine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BANDIERA SILVIO ET AL: "A single immunogenicity assay for testing potency of combination DTaP vaccines: Simultaneous quantitation of anti-DT, anti-TT, anti-PTxd and anti-FHA antibodies in Guinea-pig serum with a Luminex -xMAP bead-based serological assay", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 61, 23 August 2019 (2019-08-23), pages 15 - 21, XP085813642, ISSN: 1045-1056, [retrieved on 20190823], DOI: 10.1016/J.BIOLOGICALS.2019.08.002 *
MASDOR NOOR AZLINA ET AL: "Subtractive inhibition assay for the detection of Campylobacter jejuni in chicken samples using surface plasmon resonance", SCIENTIFIC REPORTS, vol. 9, no. 1, 1 January 2019 (2019-01-01), pages 13642, XP093022376, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754509/pdf/41598_2019_Article_49672.pdf> DOI: 10.1038/s41598-019-49672-2 *
SKOTTRUP ET AL: "Monoclonal antibodies for the detection of Puccinia striiformis urediniospores", MYCOLOGICAL RESEARCH, ELSEVIER, GB, vol. 111, no. 3, 1 March 2007 (2007-03-01), pages 332 - 338, XP022015904, ISSN: 0953-7562, DOI: 10.1016/J.MYCRES.2006.11.010 *
SKOTTRUP ET AL: "Rapid determination of Phytophthora infestans sporangia using a surface plasmon resonance immunosensor", JOURNAL OF MICROBIOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 68, no. 3, 16 February 2007 (2007-02-16), pages 507 - 515, XP005892088, ISSN: 0167-7012, DOI: 10.1016/J.MIMET.2006.10.011 *
YIXIAN WANG ET AL: "Subtractive inhibition assay for the detection of E.coli O157:H7 using surface plasmon resonance", vol. 11, no. 3, 1 January 2011 (2011-01-01), pages 2728 - 2739, XP003029230, ISSN: 1424-8220, Retrieved from the Internet <URL:http://www.mdpi.com/1424-8220/11/3/2728> [retrieved on 20110301], DOI: 10.3390/S110302728 *

Also Published As

Publication number Publication date
WO2023067031A2 (fr) 2023-04-27
GB202115077D0 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
MA46299B1 (fr) Molécule de polypeptide à double spécificité améliorée
UA95329C2 (ru) Собачий тимусный стромальный лимфопоэтин и его применение
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
MX2010003380A (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina.
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
WO2008098917A3 (fr) Nouveaux anticorps
WO2007116360A3 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
BRPI0507433B8 (pt) anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
MX2010001237A (es) Nuevos anticuerpos.
NZ615441A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
BRPI0411854A (pt) veìculos protéicos para vacinas
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2008143697A3 (fr) Anticorps a selectivite de proteine a
NZ583894A (en) Antibodies that bind to a non atp binding p2x7 receptor
WO2008140570A3 (fr) Anticorps à sélectivité de protéine a
EP4249511A3 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
WO2008113916A3 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l&#39;enveloppe de herv-w
WO2010009856A3 (fr) Protéine de liaison d’antigène goodpasture et sa détection
WO2023067031A3 (fr) Dosage
WO2007026078A3 (fr) Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22809341

Country of ref document: EP

Kind code of ref document: A2